| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks
1 company
Marcus Chapman last filed a Form 4 in February 2021, as See Remarks at MCRB. Marcus Chapman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 8,600 shares of MCRB. The MCRB filings lean toward selling, a net 3,400 shares.
Marcus Chapman has 4 Form 4 filings on record from November 2019 to February 2021, all as Seres Therapeutics (MCRB), 2019–2021.
The 6 reported transactions were 4 option or other derivative awards, 1 option exercise and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $13K.
The only open-market sale was 3,400 shares of MCRB at an average $3.91 on November 22, 2019, about $13K.
Shares as reported in the last Form 4 for each company; the most recent is from February 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 22, 2019 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE | 3,400 | $3.91 | $13,296.72 | -28.3% |